In conclusion, this study underscores the promising potential of synNotch receptor-engineered NK cells in augmenting antitumor activity, with a specific focus on addressing the breast cancer cells characterized by elevated PDL1 expression. The gene discussed is CD274; the disease is breast carcinoma.